Daxxify Injection, Powder, Lyophilized, For Solution
NDC Package 72960-112-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Daxxify (botulinum toxin type a) injection is dAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Revance Therapeutics, Inc., this product is identified by NDC 72960-112 and is authorized under FDA application BLA761127.

Identification & Billing

NDC Package Code
72960-112-06
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
Product Code
72960-112
11-Digit Billing Format
72960011206
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Daxxify
Non-Proprietary Name
Botulinum Toxin Type A
Substance Name
Botulinum Toxin Type A
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
BOTULINUM TOXIN TYPE A 100 U/1.2mL
Pharmacologic Class
Usage Information
DAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Regulatory & Marketing

Labeler Name
Revance Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761127
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-20-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72960-112). Click a package code to view its specific billing and regulatory data.

72960-112-01
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
72960-112-02
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
72960-112-05
1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72960-112-06 identifies a specific commercial package of 1 vial, single-use in 1 carton / 1.2 ml in 1 vial, single-use of Daxxify, a human prescription drug labeled by Revance Therapeutics, Inc.. This injection, powder, lyophilized, for solution is formulated for intramuscular use and contains botulinum toxin type a as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Revance Therapeutics, Inc. on September 20, 2022. The current certification is valid through December 31, 2027.

How is this Revance Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72960011206. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72960-112-06
11-Digit CMS (5-4-2)
72960-0112-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.